<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50745">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445586</url>
  </required_header>
  <id_info>
    <org_study_id>ML29282</org_study_id>
    <nct_id>NCT02445586</nct_id>
  </id_info>
  <brief_title>Safety Study of Pertuzumab (In Combination With Trastuzumab and Docetaxel) in Indian Patients With Breast Cancer</brief_title>
  <official_title>A Phase IV, Multicenter, Open-Label, Single Arm Study of Pertuzumab (In Combination With Trastuzumab and Docetaxel) In First Line Treatment of Indian Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      Study of Pertuzumab (In Combination with Trastuzumab and Docetaxel) in Indian Patients with
      Breast Cancer
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse Events (AEs), Serious Adverse Events (SAEs), Laboratory Parameters, Left Ventricular Ejection Fraction (LVEF), Congestive Heart Failure (CHF) and/or Significant Decline in LVEF</measure>
    <time_frame>Up to 24 months after the last patient in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 24 months after the last patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 months after the last patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months after the last patient in</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pertuzumab in Combination with Trastuzumab and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment cycle of Pertuzumab is 3 weeks (21 days) in duration. The initial dose (Cycle 1, Day 1) of pertuzumab will be 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel should be administered after pertuzumab and trastuzumab.</description>
    <arm_group_label>Pertuzumab in Combination with Trastuzumab and Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>The initial dose (Cycle 1, Day 1) will be 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.</description>
    <arm_group_label>Pertuzumab in Combination with Trastuzumab and Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Initial dose of trastuzumab was 8 mg/kg administered as a 90-minute intravenous infusion, followed every 3 weeks by a dose of 6 mg/kg administered as an intravenous infusion over 30 to 90 minutes.</description>
    <arm_group_label>Pertuzumab in Combination with Trastuzumab and Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged &gt;/= 18 years

          2. Signed written informed consent approved by the relevant Institutional Review
             Board/Ethics Committee, prior to any study procedure

          3. For women of childbearing potential and men with partners of childbearing potential,
             agreement to use a highly-effective non-hormonal form of contraception or two
             effective forms of non-hormonal contraception by the patient and/or partner.

          4. Histologically or cytologically confirmed and documented adenocarcinoma of the breast
             with metastatic or locally recurrent disease not amenable to curative resection;
             patients with measurable and/or non-measurable disease are eligible

          5. Known and documented HER2-positive

          6. Known and documented left ventricular ejection fraction (LVEF) of at least 50%

          7. Adequate organ function

        Exclusion Criteria:

          1. Previous systemic non-hormonal anti-cancer therapy for the metastatic or locally
             recurrent disease

          2. Pregnant or lactating women

          3. Current clinical or radiographic evidence of central nervous system (CNS) metastases

          4. Disease progression while receiving or within 12 months of completion of trastuzumab
             and/or lapatinib treatment in the adjuvant or neoadjuvant setting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Kukreja, MD</last_name>
    <role>Study Director</role>
    <affiliation>Roche Products (India) Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700156</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delhi</city>
        <zip>110092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <zip>500 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>May 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
